Qlaira Consumer Site

Expert Tutorials

Key Qlaira® topics
View Now  
Expert tutorials about key Qlaira® topics

Frequently Asked Questions

For clinicians
Read Now  
Frequently asked questions about Qlaira®

Patient Support

Tools & FAQs
View Now  
Missed pill tool and FAQs

Qlaira®: First in a New Class of Oral Contraceptives

Reliable contraception and
good cycle control.2,3

First in a new class

Drawing on more than 75 years of innovation in contraception, Bayer HealthCare Pharmaceuticals has created Qlaira® (estradiol valerate/dienogest), the first and only oral contraceptive to deliver 17β-estradiol (E2), the same estrogen produced in the female body, establishing a new class of birth control pill.4

Qlaira® combines estradiol valerate (E2V) with dienogest (DNG) in a 26/2 regimen that provides reliable contraception together with a good bleeding profile for the first time in an E2-based OC.2,3

Patient satisfaction with Qlaira®

Well-tolerated and associated with high satisfaction rates in studies, Qlaira® provides another option for women interested in hormonal contraception.2

So learn more about Qlaira®, its contraceptive efficacy, use in the treatment of heavy menstrual bleeding, pharmacokinetics and safety and tolerability. You can also review data from the Qlaira® clinical studies and access tools and resources to help support your practice and educate women about Qlaira®.

*Qlaira® is approved for the treatment of HMB without organic pathology in women who desire oral contraception.4

For Qlaira®, the registration procedure for the indication “treatment of heavy menstrual bleeding (HMB) in women without organic pathology who desire oral contraception” was successfully concluded in October 2010 in the European Union. Implementation of registrations at the country level is ongoing.

The indication “treatment of heavy and/or prolonged menstrual bleeding (HPMB) in women without organic pathology who desire oral contraception” was granted in Australia, and license applications have also been submitted in the United States of America (USA) and to health authorities in other countries.

References:

  1. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258-269. http://informahealthcare.com/doi/full/10.3109/13625187.2011.591456. Accessed August 5, 2011.
  2. Palacios S, Wildt L, Parke S, Machlitt A, Römer R, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial. Eur J Obstet Gynecol. 2010;149(1):57-62.
  3. Ahrendt H-J, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinylestradiol/levonorgestrel. Contraception. 2009;80(5):436-444.
  4. Qlaira® EU Summary of Product Characteristics 08 Oct 2010. Available in the database of the Heads of Medicines Agencies' website: http://www.hma.eu/mri.html.
    Please refer to your local Summary of Product Characteristics applicable for your country which may differ from this document.